Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Austria | Belgium | Bulgaria | Croatia | Cyprus | France | Germany | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Malta | New Zealand | Pakistan | Philippines | Poland | Portugal | Russia | Serbia | Singapore | South Africa | Spain | Taiwan | Thailand | Tunisia | Turkey | United Arab Emirates | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Diarrhea|CHARGE Syndrome|Spasm
Phase 3: Constipation|Dyspepsia|Gastritis
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CO-161213141338-DHCT | P1 |
Completed |
Healthy Volunteers |
2019-12-26 |
27% |
CO-150121160547-DHCT | P3 |
Completed |
Dyspepsia|Gastritis |
2016-10-01 |
|
NICEVIS Version 1.0 | P2 |
Completed |
Unknown |
2014-04-24 |
|
2009-013049-27 | P4 |
Completed |
CHARGE Syndrome|Spasm |
2011-10-06 |